Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.99 Million SEK | -2259.71% |
| 2022 | -2.79 Million SEK | 23.14% |
| 2021 | -3.63 Million SEK | -514.38% |
| 2020 | 876 Thousand SEK | 110.58% |
| 2019 | 416 Thousand SEK | -18.27% |
| 2018 | 509 Thousand SEK | -86.06% |
| 2017 | 3.65 Million SEK | 1.85% |
| 2016 | 3.58 Million SEK | 6818.74% |
| 2015 | -53.34 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 100.0% |
| 2012 | -11.39 Million SEK | -3355.32% |
| 2011 | 349.99 Thousand SEK | -0.14% |
| 2010 | 350.48 Thousand SEK | 75.24% |
| 2009 | 199.99 Thousand SEK | 33.33% |
| 2008 | 149.99 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.87 Million SEK | 524.56% |
| 2024 Q1 | -676 Thousand SEK | 96.64% |
| 2024 Q3 | -9.29 Million SEK | -423.94% |
| 2023 Q1 | -48 Thousand SEK | -71.43% |
| 2023 Q4 | -20.14 Million SEK | -1457.61% |
| 2023 Q2 | 84 Thousand SEK | 275.0% |
| 2023 FY | -65.83 Million SEK | -2259.71% |
| 2023 Q3 | 1.48 Million SEK | 1666.67% |
| 2022 Q4 | -28 Thousand SEK | 96.67% |
| 2022 Q1 | -408 Thousand SEK | 90.44% |
| 2022 Q2 | -1.51 Million SEK | -270.59% |
| 2022 FY | -2.79 Million SEK | 23.14% |
| 2022 Q3 | -842 Thousand SEK | 44.31% |
| 2021 Q1 | 632 Thousand SEK | 412.87% |
| 2021 Q3 | -7000.00 SEK | 99.08% |
| 2021 Q4 | -4.27 Million SEK | -60900.0% |
| 2021 FY | -3.63 Million SEK | -514.38% |
| 2021 Q2 | -765 Thousand SEK | -221.04% |
| 2020 Q4 | -202 Thousand SEK | -128.9% |
| 2020 Q2 | 289 Thousand SEK | 221.11% |
| 2020 FY | 876 Thousand SEK | 110.58% |
| 2020 Q1 | 90 Thousand SEK | 143.06% |
| 2020 Q3 | 699 Thousand SEK | 141.87% |
| 2019 Q4 | -209 Thousand SEK | -159.38% |
| 2019 FY | 416 Thousand SEK | -18.27% |
| 2019 Q3 | 352 Thousand SEK | 83.33% |
| 2019 Q1 | 81 Thousand SEK | 180.22% |
| 2019 Q2 | 192 Thousand SEK | 137.04% |
| 2018 FY | 509 Thousand SEK | -86.06% |
| 2018 Q1 | -80.01 Thousand SEK | -118.7% |
| 2018 Q4 | -100.96 Thousand SEK | -135.83% |
| 2018 Q3 | 281.76 Thousand SEK | -30.98% |
| 2018 Q2 | 408.22 Thousand SEK | 610.16% |
| 2017 FY | 3.65 Million SEK | 1.85% |
| 2017 Q4 | 427.92 Thousand SEK | -86.72% |
| 2017 Q3 | 3.22 Million SEK | 32.22% |
| 2017 Q2 | 2.43 Million SEK | 1.75% |
| 2017 Q1 | 2.39 Million SEK | -1.43% |
| 2016 FY | 3.58 Million SEK | 6818.74% |
| 2016 Q2 | 5945.00 SEK | 1.05% |
| 2016 Q1 | 5883.00 SEK | 100.06% |
| 2016 Q3 | 1.19 Million SEK | 20013.39% |
| 2016 Q4 | 2.42 Million SEK | 103.21% |
| 2015 Q3 | -3.14 Million SEK | -3.55% |
| 2015 Q4 | -10.3 Million SEK | -228.21% |
| 2015 FY | -53.34 Thousand SEK | 0.0% |
| 2015 Q2 | -3.03 Million SEK | -264740.23% |
| 2015 Q1 | 1146.00 SEK | -99.98% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | 7.53 Million SEK | 389.49% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q3 | -2.6 Million SEK | 0.0% |
| 2014 Q1 | - SEK | 100.0% |
| 2013 Q4 | -10.69 Million SEK | -200.54% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q3 | -3.55 Million SEK | 0.0% |
| 2013 FY | - SEK | 100.0% |
| 2013 Q1 | - SEK | 100.0% |
| 2012 Q4 | -3.52 Million SEK | -29.77% |
| 2012 Q2 | 23.13 Thousand SEK | -76.86% |
| 2012 Q1 | 99.99 Thousand SEK | -42.86% |
| 2012 FY | -11.39 Million SEK | -3355.32% |
| 2012 Q3 | -2.71 Million SEK | -11841.98% |
| 2011 Q3 | - SEK | -100.0% |
| 2011 Q2 | 175 Thousand SEK | 0.0% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q4 | 174.99 Thousand SEK | 0.0% |
| 2011 FY | 349.99 Thousand SEK | -0.14% |
| 2010 Q2 | 175 Thousand SEK | 0.0% |
| 2010 FY | 350.48 Thousand SEK | 75.24% |
| 2010 Q3 | - SEK | -100.0% |
| 2010 Q1 | - SEK | -100.0% |
| 2010 Q4 | 175.48 Thousand SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2009 Q1 | - SEK | 0.0% |
| 2009 FY | 199.99 Thousand SEK | 33.33% |
| 2009 Q4 | 199.99 Thousand SEK | 0.0% |
| 2009 Q3 | - SEK | 0.0% |
| 2008 FY | 149.99 Thousand SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| 2008 Q3 | - SEK | -100.0% |
| 2008 Q2 | 99.99 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 43.421% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 99.003% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 99.003% |
| Arcoma AB | 11.07 Million SEK | 72.929% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 97.859% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.836% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 98.8% |
| CellaVision AB (publ) | 463.04 Million SEK | 99.353% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 110.548% |
| C-Rad AB (publ) | 66.01 Million SEK | 95.46% |
| Duearity AB (publ) | -4.17 Million SEK | 171.733% |
| Dignitana AB (publ) | 58.97 Million SEK | 94.918% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 107.17% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.978% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 105.968% |
| Iconovo AB (publ) | 17.57 Million SEK | 82.95% |
| Integrum AB (publ) | 690.56 Thousand SEK | -333.994% |
| Luxbright AB (publ) | -2.79 Million SEK | 207.155% |
| Mentice AB (publ) | 236.38 Million SEK | 98.732% |
| OssDsign AB (publ) | 83.64 Million SEK | 96.417% |
| Paxman AB (publ) | 12.61 Million SEK | 76.248% |
| Promimic AB (publ) | 38.51 Million SEK | 92.219% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 105.905% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 81.312% |
| ScandiDos AB (publ) | 47.55 Million SEK | 93.698% |
| Sectra AB (publ) | 557.55 Million SEK | 99.462% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 97.25% |
| Senzime AB (publ) | 8.33 Million SEK | 64.06% |
| SpectraCure AB (publ) | -9.22 Million SEK | 132.495% |
| Stille AB | 132.17 Million SEK | 97.732% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.848% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 99.281% |